SQ3370 is an experimental two-part treatment from Shasqi: a gel injected into a tumour, then an inactive form of the chemotherapy drug doxorubicin given into a vein, which the gel switches on. In its one trial, very high doses caused no dose-limiting side effects, but tumours responded no more often than with ordinary doxorubicin and the trial was stopped. It is not approved anywhere.
SQ3370 is the first product of Shasqi's click-activated prodrug platform and, according to the company and the paper reporting it, the first use of click chemistry inside the human body in a clinical setting. It has two components that are given separately: SQL70, a tetrazine-modified hyaluronate biopolymer injected into one lesion, and SQP33, a trans-cyclooctene-modified doxorubicin prodrug infused daily. SQP33 was chosen in laboratory work from capped forms of four cytotoxic drugs.
Its only registered trial is NCT04106492, a phase 1/2a open-label study at ten centres in the United States and Australia that started in August 2020 and enrolled 53 people. Phase 1 (39 patients with advanced solid tumours) gave doxorubicin-equivalent doses from 0.38 to 15 times the standard dose per cycle with no dose-limiting toxicity reported and, in the authors' words, mild and manageable myelosuppression; 12 times the standard dose was chosen as the recommended phase 2 dose. Active doxorubicin was released rapidly at every dose level tested, and tumour and blood samples showed expansion and activation of cytotoxic CD8 T cells.
Phase 2a treated 14 patients with soft tissue sarcoma at the recommended dose. Two had an unconfirmed objective response (14.3 per cent) and ten had disease control (71.4 per cent, 95% CI 41.9 to 91.6). The authors state that the response rate was comparable to standard doxorubicin and that the study was terminated because the prespecified criterion for continuing, a response rate greater than that of standard doxorubicin, was not met. The registry gives the reason for stopping as the sponsor's decision, with primary completion on 7 September 2023.
No regulator has approved SQ3370 and no trial of it is open. Shasqi's pipeline, read on 16 November 2026, shows the biopolymer and doxorubicin programme for sarcoma as having reached the clinic and marks it "Partnering"; the company's June 2025 press release describes Shasqi as a preclinical company, and its newer programmes pair the same chemistry with tumour-binding proteins instead of an injected biopolymer.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
SQL70, a tetrazine-modified sodium hyaluronate biopolymer, is injected into a tumour. SQP33, doxorubicin capped with a trans-cyclooctene group that attenuates its activity, is then infused. Where SQP33 meets SQL70 the two react (a click reaction), the prodrug is captured at the tumour and native doxorubicin is released there.
1.SQL70, a biopolymer carrying tetrazine groups, is injected into one tumour on day 1 of a 21-day cycle.
Source: clinicaltrials.gov/study/NCT04106492?tab=results. Doses are for orientation; the current label governs.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
It establishes that a click reaction between two separately given substances can be run inside a person, and that capping doxorubicin this way lets far more of it be given. It does not establish that patients do better: the abstract reports no tumour responses, and the trial's phase 2a part later found a response rate comparable to standard doxorubicin.
For a person with sarcoma, this is a treatment that was easier to tolerate than its dose would suggest but did not work better than doxorubicin in the small group tested, and it is not available. For the field, it is the human proof that click activation works as chemistry, which is why the company has moved to versions guided by tumour-binding proteins.
It names the two components of SQ3370 and the reaction that joins them, and shows the design is modular: the same activator can switch on different capped drugs.
This is the animal evidence behind the hope that treating one injectable tumour could help disease elsewhere. In the human trial that followed, shrinkage of non-injected lesions was seen, but the overall response rate was no higher than with standard doxorubicin.
This is the origin of the approach, published four years before the first patient was treated.
Query for this drug: (TITLE:"SQ3370" OR ABSTRACT:"SQ3370" OR TITLE:"SQL70 plus SQP33" OR ABSTRACT:"SQL70 plus SQP33" OR TITLE:"SQL70" OR ABSTRACT:"SQL70" OR TITLE:"SQP33" OR ABSTRACT:"SQP33" OR TITLE:"doxorubicin protodrug SQP33" OR ABSTRACT:"doxorubicin protodrug SQP33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SQ3370, not a curated reading list.
Shares Sarcomas (soft tissue, bone, GIST) and the tag failure.
Shares Sant P. Chawla, SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), Sarcomas (soft tissue, bone, GIST).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Dose-limiting toxicity (DLT), Recommended phase 2 dose (RP2D).
Shares Dose-limiting toxicity (DLT), Recommended phase 2 dose (RP2D).
Shares Sant P. Chawla, Doxorubicin, Sarcomas (soft tissue, bone, GIST).
Shares Sant P. Chawla, Doxorubicin, Sarcomas (soft tissue, bone, GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/